Combination composition, comprising as active ingredients L-carnitine or propionyl L-carnitine, for the prevention or treatment of chronic venous insufficiency

Abstract

A combination composition comprising as active ingredients L-carnitine or propionyl L-carnitine, troxerutine, diosmine and hesperidine, useful for the prevention and/or treatment of chronic venous diseases.

1 . Combination composition comprising L-carnitine or a derivative or a salt thereof, troxerutine, diosmine and hesperidine. 
     
     
         2 . Combination composition of  claim 1 , further comprising one or more pharmaceutically acceptable excipients. 
     
     
         3 . Combination composition of  claim 1 , in which the derivative of L-carnitine is propionyl L-carnitine. 
     
     
         4 . Combination composition of  claim 1 , comprising:
 from 10 to 3000 mg of L-carnitine or propionyl L-carnitine;   from 50 mg to 900 mg of troxerutine;   from 50 mg to 900 mg of diosmine; and   from 10 mg to 500 mg of hesperidine.   
     
     
         5 . Combination composition of  claim 4 , wherein the L-carnitine or the propionyl L-carnitine is in a dose of from 50 mg to 400 mg. 
     
     
         6 . Combination composition of  claim 4 , wherein the L-carnitine or the propionyl L-carnitine is in a dose of 136 mg. 
     
     
         7 . Combination composition of  claim 4 , wherein the troxerutine is in a dose of from 200 mg to 400 mg. 
     
     
         8 . Combination composition of  claim 4 , wherein the troxerutine is in a dose of 300 mg. 
     
     
         9 . Combination composition of  claim 4 , wherein the diosmine is in a dose of from 200 mg to 400 mg. 
     
     
         10 . Combination composition of  claim 4 , wherein the diosmine is in a dose of 300 mg. 
     
     
         11 . Combination composition of  claim 4 , wherein the hesperidine is in a dose of from 50 mg to 200 mg. 
     
     
         12 . Combination composition of  claim 4 , wherein the hesperidine is in a dose of 100 mg. 
     
     
         13 . Combination composition of  claim 1 , further comprising co-enzymes, mineral substances, antioxidants, vitamins and anticloting agents. 
     
     
         14 . A method of treating diseases of the veins, comprising:
 administering to a patient in need thereof an effective amount of a combination composition of  claim 1 .   
     
     
         15 . Method of  claim 14 , wherein the derivative of L-carnitine is propionyl L-carnitine. 
     
     
         16 . Method of  claim 14 , wherein the diseases of the veins are selected from the group consisting of: chronic venous insufficiency, chronic venous disease and complications thereof. 
     
     
         17 . Method of  claim 15 , wherein said complications are selected from the group consisting of: swelling and inflammation of veins in the rectum, anus and vulva; venous hypertension; increased permeability; edema; capillary damage; skin changes; venous leg ulcers; swelling ankles; heavy legs; varicose veins; swelling leg; ulcers; vein thrombosis; phlebitis; thrombo-phlebitis; pulmonary embolus or hemorrhoids. 
     
     
         18 . Method of  claim 14 , wherein the salt of L-carnitine or propionyl L-carnitine is selected from the group consisting of: chloride, bromide, orotate, aspartate, acid aspartate, acid citrate, magnesium citrate, phosphate, acid phosphate, fumarate and acid fumarate, magnesium fumarate, lactate, maleate and acid maleate, oxalate, acid oxalate, pamoate, acid pamoate, sulphate, acid sulphate, glucose phosphate, tartrate and acid tartrate, glycerophosphate, mucate, magnesium tartrate, 2-amino-ethanesulphonate, magnesium 2-amino-ethanesulphonate, methanesulphonate, choline tartrate, trichloroacetate, and trifluoroacetate. 
     
     
         19 . Method of  claim 14 , wherein the combination composition is for oral, parenteral, intravenous, topical and/or transdermal administration. 
     
     
         20 . Method of  claim 19 , wherein the combination composition is for oral administration.